Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (1878)	3/17/2016 11:27:13 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

For Eylea few more months and it is over. For Praluent, they have from 2013 (plenty of time) to negotiate decent royalty deal that would be satisfactory to both party. Yes, AMGN is playing game by patenting structure (antibody binding to PCSK-9 domein fragment and certain amino-acids residues on that fragment, in junction with LDL-receptor) of the antibody interaction with target (that both Repatha and Praluent use), but that is how IP system work in US. So, IF Repatha CVOT results are better than expected, be ASSURE that AMGN will ask for higher royalty rate (higher that 5%)! As SH I would prefer to avoid this point-in-time uncertainty.